Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase I for Gastrointestinal Tumor.

This is based on reported shares across multiple companies, which include IMMUNOMEDICS INC, FENNEC PHARMACEUTICALS INC., Gain Therapeutics, Inc., and Processa Pharmaceuticals, Inc.. Attention ...

This page features the latest news about the Processa Pharmaceuticals share. Processa Pharmaceuticals stock hits 52-week low at $1.3 Processa Pharmaceuticals Inc. shares have touched a 52-week low, ...

Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety. The company ...

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences ...

Recursion Pharmaceuticals Inc RXRX shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).

Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of ...

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during ...